November 28, 2021

Medical Trend

Medical News and Medical Resources

AstraZeneca’s Imfinzi+tremelimumab Phase 3 trials: More effective

AstraZeneca's Imfinzi+tremelimumab Phase 3 trials: More effective

AstraZeneca’s Imfinzi+tremelimumab Phase 3 trials: More effective than Sorafenib and prolongs survival!



 

First-line treatment of liver cancer (HCC) with dual immunity! AstraZeneca’s Imfinzi+tremelimumab Phase 3 clinical trial: Curative effect defeats Sorafenib and prolongs survival!

Imfinzi and tremelimumab are immune checkpoint inhibitors. Imfinzi can block PD-L1, and tremelimumab can block CTLA-4.

 

AstraZeneca recently announced a high level of positive results from the HIMALAYA Phase 3 trial.

Data show that in patients with unresectable hepatocellular carcinoma (HCC) who have not previously received systemic treatment and are not eligible for local treatment, compared with the multi-kinase inhibitor sorafenib (sorafenib), a single high starting dose Tremelimumab (anti-CTLA-4 monoclonal antibody) was added to the anti-PD-L1 therapy Imfinzi (generic name: durvalumab) for first-line treatment, showing statistically significant and clinically significant overall survival (OS) benefit.

 

This new dosing and treatment regimen composed of anti-CTLA-4 monoclonal antibodies tremelimumab and Imfinzi is called STRIDE regimen (single dose of tremelimumab + regular interval dosing [once in 4 weeks] durvalumab) .

In this study, the combination drug showed good safety, and the addition of tremelimumab to Imfinzi did not increase severe liver toxicity. In this study, compared with sorafenib, Imfinzi monotherapy showed non-inferiority in terms of OS, the numerical trend was in favor of Imfinzi, and the tolerability was also improved.

 

HCC is the most common type of liver cancer. Globally, liver cancer is the third leading cause of cancer deaths and the sixth most common cancer. Approximately 900,000 people are diagnosed with liver cancer each year . Only 7% of advanced patients can survive for 5 years.

 

Imfinzi and tremelimumab are immune checkpoint inhibitors. Among them, Imfinzi is a monoclonal antibody that targets PD-L1, which can block the binding of PD-L1 to PD-1 and CD80, thereby blocking tumor immune escape and releasing suppressed immune responses.

Tremelimumab is a monoclonal antibody targeting CTLA-4, which can block the activity of CTLA-4, promote T cell activation, initiate tumor immune response, and promote cancer cell death. Tremelimumab and Bristol-Myers Squibb’s listed antibody drug Yervoy ( generic name: Ipilimumab) target the same target CTLA-4.

 

Ghassan Abou Alfa, chief investigator of the HIMALAYA Phase 3 trial and attending physician at Memorial Sloan Kettering Cancer Center, said: “HIMALAYA is the first to add a novel single-start-dose anti-CTLA4 antibody to another checkpoint inhibitor durvalumab. Phase trial. This helps strengthen the patient’s own immune system to fight liver cancer , with the goal of maximizing long-term survival while minimizing side effects. This is very exciting news for our patients.”

 

Susan Galbraith, Executive Vice President of Oncology Research and Development at AstraZeneca , said: “Inhibition of CTLA-4 has been shown to be beneficial in several situations, especially at the end of the survival curve. This is the first time that dual immunotherapy has been used as a first-line treatment. The program has improved the overall survival of patients with unresectable liver cancer . For these patients, treatment options are limited and the long-term efficacy is poor.”

 

 

 

AstraZeneca’s Imfinzi+tremelimumab Phase 3 trials: More effective

(source:internet, reference only)


Disclaimer of medicaltrend.org